Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind active-controlled study of prasugrel hydrochloride tablets in acute coronary syndrome patients planned for PCI
CTR20254320Phase 3Active
- Sponsor
- Chongqing Pharmaceutical (Group) Co., Ltd.
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of prasugrel in acute coronary syndrome (ACS), sponsored by Chongqing Pharmaceutical (Group) Co., Ltd.. Started Jan 2026; status: active.
02
Drugs
prasugrel
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on CTR20254320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254320.